In this study, we conducted a comparative analysis of the most significant CRC mutations—APC, TP53, KRAS, BRAF, NRAS, and ERBB2—between publicly available databases, subsequently referred to as the clinical cohort, and PDX models, referred to as the PDX cohort, from our institution. This evidence concerns the gene BRAF and colorectal carcinoma.